BioAtla, Inc. (NASDAQ:BCAB) Short Interest Update

BioAtla, Inc. (NASDAQ:BCAB) was the target of a large increase in short interest during the month of August. As of August 15th, there was short interest totalling 4,750,000 shares, an increase of 18.8% from the July 31st total of 4,000,000 shares. Based on an average daily volume of 955,100 shares, the short-interest ratio is presently 5.0 days.

BioAtla Stock Down 2.7 %

Shares of NASDAQ:BCAB traded down $0.05 during trading on Friday, reaching $1.77. 457,341 shares of the company traded hands, compared to its average volume of 1,033,127. The firm has a market capitalization of $85.17 million, a PE ratio of -0.71 and a beta of 1.06. BioAtla has a 52 week low of $1.14 and a 52 week high of $4.02. The company’s 50 day moving average is $1.63 and its two-hundred day moving average is $2.20.

BioAtla (NASDAQ:BCAB) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.01. During the same quarter in the prior year, the firm posted ($0.75) EPS. As a group, research analysts anticipate that BioAtla will post -1.51 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in BCAB. AQR Capital Management LLC bought a new stake in BioAtla during the second quarter worth $872,000. Scion Asset Management LLC bought a new stake in shares of BioAtla during the 2nd quarter worth $869,000. Bank of Montreal Can boosted its stake in BioAtla by 55.1% in the second quarter. Bank of Montreal Can now owns 404,198 shares of the company’s stock valued at $554,000 after buying an additional 143,521 shares in the last quarter. Chase Investment Counsel Corp bought a new position in BioAtla in the first quarter valued at about $263,000. Finally, Dimensional Fund Advisors LP raised its stake in BioAtla by 28.3% during the second quarter. Dimensional Fund Advisors LP now owns 333,858 shares of the company’s stock worth $458,000 after acquiring an additional 73,598 shares in the last quarter. 77.23% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. HC Wainwright restated a “buy” rating and issued a $7.00 price target on shares of BioAtla in a research note on Wednesday, May 15th. JMP Securities decreased their target price on shares of BioAtla from $12.00 to $5.00 and set a “market outperform” rating on the stock in a research report on Thursday, May 23rd.

About BioAtla

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.